CY1120187T1 - Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης - Google Patents

Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης

Info

Publication number
CY1120187T1
CY1120187T1 CY20181100459T CY181100459T CY1120187T1 CY 1120187 T1 CY1120187 T1 CY 1120187T1 CY 20181100459 T CY20181100459 T CY 20181100459T CY 181100459 T CY181100459 T CY 181100459T CY 1120187 T1 CY1120187 T1 CY 1120187T1
Authority
CY
Cyprus
Prior art keywords
methods
sildenafil citrate
preparation
sildenafil
solutions
Prior art date
Application number
CY20181100459T
Other languages
English (en)
Inventor
Moshe Rogosnitzky
Morris ABOOHI
Original Assignee
Vigorous Solutions Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120187(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vigorous Solutions Ltd. filed Critical Vigorous Solutions Ltd.
Publication of CY1120187T1 publication Critical patent/CY1120187T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00Details of, or arrangements associated with, antennas
    • H01Q1/27Adaptation for use in or on movable bodies
    • H01Q1/28Adaptation for use in or on aircraft, missiles, satellites, or balloons
    • H01Q1/288Satellite antennas
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00Details of, or arrangements associated with, antennas
    • H01Q1/36Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
    • HELECTRICITY
    • H01ELECTRIC ELEMENTS
    • H01QANTENNAS, i.e. RADIO AERIALS
    • H01Q5/00Arrangements for simultaneous operation of antennas on two or more different wavebands, e.g. dual-band or multi-band arrangements
    • H01Q5/50Feeding or matching arrangements for broad-band or multi-band operation
    • H01Q5/55Feeding or matching arrangements for broad-band or multi-band operation for horn or waveguide antennas

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Astronomy & Astrophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Remote Sensing (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αναφέρεται σε συνθέσεις που περιέχουν διαλυμένο κιτρικό άλας σιλδεναφίλης και σε μεθόδους παραγωγής τέτοιων συνθέσεων, όπου το κιτρικό άλας σιλδεναφίλης διαλύεται σε νερό αναμεμειγμένο με μία ή περισσότερες αλκοόλες και προαιρετικά μπορεί να χρησιμοποιηθεί μια κετόνη για την αύξηση της διαλυτότητας. Επίσης αναφέρεται σε μεθόδους χρήσης τέτοιων συνθέσεων που περιέχουν διαλυμένο κιτρικό άλας σιλδεναφίλης χρησιμοποιώντας δόσεις σημαντικά κάτω από τις υπάρχουσες θεραπευτικές δοσολογίες κιτρικού άλατος σιλδεναφίλης.
CY20181100459T 2014-03-19 2018-05-03 Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης CY1120187T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955299P 2014-03-19 2014-03-19
PCT/IB2015/052014 WO2015140748A2 (en) 2014-03-19 2015-03-19 Sildenafil solutions and methods of making and using same

Publications (1)

Publication Number Publication Date
CY1120187T1 true CY1120187T1 (el) 2018-12-12

Family

ID=54145440

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100459T CY1120187T1 (el) 2014-03-19 2018-05-03 Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης

Country Status (24)

Country Link
US (2) US9968609B2 (el)
EP (2) EP3372083A1 (el)
JP (1) JP6744821B2 (el)
KR (1) KR20160137584A (el)
CN (1) CN106132204B (el)
AU (2) AU2015233006B2 (el)
CA (1) CA2942628C (el)
CL (1) CL2016002318A1 (el)
CY (1) CY1120187T1 (el)
DK (1) DK3119201T3 (el)
EA (1) EA032819B1 (el)
ES (1) ES2668915T3 (el)
HR (1) HRP20180773T1 (el)
HU (1) HUE038431T2 (el)
IL (1) IL247840B (el)
LT (1) LT3119201T (el)
MX (1) MX371276B (el)
NO (1) NO2723977T3 (el)
PL (1) PL3119201T3 (el)
PT (1) PT3119201T (el)
RS (1) RS57206B1 (el)
SG (2) SG11201607507VA (el)
SI (1) SI3119201T1 (el)
WO (1) WO2015140748A2 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2723977T3 (el) 2014-03-19 2018-03-10
JP6902372B2 (ja) * 2017-02-28 2021-07-14 ヱスビー食品株式会社 苦味抑制用組成物
AU2018397436A1 (en) * 2017-12-26 2020-08-13 Ftf Pharma Private Limited Liquid oral formulations for PDE V inhibitors
EP3956024A4 (en) * 2019-04-18 2023-01-11 Ellamed IP & Services Pte. Ltd. SILDENAFIL CITRATE LIQUID COMPOSITIONS
AU2020382492A1 (en) * 2019-11-12 2022-05-26 American Regent, Inc. Type V phosphodiesterase inhibitor compositions, methods of making them and methods of using them

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017675A1 (en) * 1993-02-05 1994-08-18 Kao Corporation Taste modifying method and bitter taste reducing method
US5785984A (en) * 1993-02-05 1998-07-28 Kao Corporation Taste-modifying method and bitterness-decreasing method
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
CA2406930C (en) 2000-02-04 2011-02-15 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2002005820A1 (en) 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US20030216407A1 (en) 2002-01-31 2003-11-20 Pfizer Inc. Use of PDE5 inhibitors in the treatment of scarring
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
US20070065394A1 (en) 2003-11-17 2007-03-22 Pinney Virginia R Compositions effective in altering the perception of malodor
ATE387203T1 (de) 2004-01-05 2008-03-15 Teva Pharma Prozesse zur herstellung von sildenafil-base und zitratsalz
CN1925860A (zh) * 2004-01-05 2007-03-07 特瓦制药工业有限公司 制备西地那非碱及其柠檬酸盐的方法
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
ES2434944T5 (es) 2005-03-14 2022-10-20 Wyeth Llc Composiciones de tigeciclina y procedimientos de preparación
US7556487B2 (en) 2006-03-29 2009-07-07 Intergum Gida Sinayi ve Ticaret A.S. Apparatus for making center-filled chewing gum pieces
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
DE502008002360D1 (de) 2007-06-19 2011-03-03 Symrise Ag Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck
EP2072044A1 (en) * 2007-12-19 2009-06-24 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising a liquid or flowable core composition
WO2009125415A1 (en) 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
FR2939321B1 (fr) 2008-12-05 2011-08-26 Philippe Perovitch Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique.
US8642270B2 (en) 2009-02-09 2014-02-04 Vm Institute Of Research Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
DE102010049708A1 (de) * 2010-10-28 2012-05-03 Hexal Ag Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe
JP6047174B2 (ja) * 2011-12-05 2016-12-21 スダ リミテッド シルデナフィルの経口スプレー製剤及びその投与方法
GB2497933B (en) 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2013170655A1 (en) * 2012-05-16 2013-11-21 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
NO2723977T3 (el) 2014-03-19 2018-03-10

Also Published As

Publication number Publication date
AU2018250378A1 (en) 2018-11-08
CN106132204B (zh) 2019-08-20
EA201691871A1 (ru) 2017-03-31
PT3119201T (pt) 2018-06-15
RS57206B1 (sr) 2018-07-31
SG11201607507VA (en) 2016-10-28
CN106132204A (zh) 2016-11-16
KR20160137584A (ko) 2016-11-30
EP3119201A4 (en) 2017-03-15
HUE038431T2 (hu) 2018-10-29
EA032819B1 (ru) 2019-07-31
IL247840B (en) 2019-03-31
LT3119201T (lt) 2018-05-10
US20170049776A1 (en) 2017-02-23
MX2016012154A (es) 2016-12-15
CL2016002318A1 (es) 2017-03-24
CA2942628A1 (en) 2015-09-24
US20180233823A1 (en) 2018-08-16
ES2668915T3 (es) 2018-05-23
PL3119201T3 (pl) 2018-08-31
EP3119201A2 (en) 2017-01-25
MX371276B (es) 2020-01-23
NO2723977T3 (el) 2018-03-10
CA2942628C (en) 2022-06-07
SG10201808038TA (en) 2018-10-30
US9968609B2 (en) 2018-05-15
JP2017508764A (ja) 2017-03-30
DK3119201T3 (en) 2018-05-28
WO2015140748A2 (en) 2015-09-24
AU2018250378B2 (en) 2020-05-14
SI3119201T1 (en) 2018-07-31
AU2015233006B2 (en) 2018-07-19
EP3119201B1 (en) 2018-03-14
HRP20180773T1 (hr) 2018-06-15
WO2015140748A3 (en) 2015-12-17
JP6744821B2 (ja) 2020-08-19
EP3372083A1 (en) 2018-09-12
US10211534B2 (en) 2019-02-19
AU2015233006A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
CY1120187T1 (el) Διαλυματα σιλδεναφιλης και μεθοδοι παρασκευης και χρησης αυτης
CL2017002728A1 (es) Método para el tratamiento de cáncer
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
CL2017000806A1 (es) Compuestos anti-tnf
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2015000227A (es) Virus de la enfermedad de newcastle y usos de los mismos
EA201790398A1 (ru) Способы лечения заболевания печени
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2016002073A1 (es) Proceso para producir una solución inyectable de noradrenalina de baja concentración estable
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
CL2017000391A1 (es) Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea
BR112017008481A2 (pt) composto antimicótico
ES2601137T3 (es) Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ECSP17029203A (es) Inhibidor de cinasa aurora a
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
ECSP16096831A (es) Derivados de naftiridinadiona